Value through Innovation27 July 2016

Clinical Study Results

  • Volasertib - Neoplasms
    Clinical Study Number 1230.27
    Study Indication Neoplasms ; Leukemia
    Product Volasertib
    Generic Name Volasertib
    Lab Code BI 6727
    Clinical Phase I
    Study Title

    Open, non-controlled, dose-escalating Phase I trial to evaluate the pharmacokinetics, pharmacodynamics, tolerability, and toxicity of volasertib in paediatric patients from 2 years to less than 18 years of age with acute leukaemia or advanced solid tumour, for whom no effective treatment is known

    Study Document Lay summary 1230.27 english
  • BI 860585 - Neoplasms
    Clinical Study Number 1325.1
    Study Indication Neoplasms
    Product BI 860585
    Generic Name BI 860585
    Lab Code BI 860585
    Clinical Phase I
    Study Title

    An open-label, Phase I, dose-finding study of BI 860585 administered orally in a continuous dosing schedule as a single agent and in combination with exemestane or with paclitaxel in patients with various advanced and/or metastatic solid tumours

    Study Document Lay summary 1325.1 english

Clinical Trial Registry and structured study results. Find here protocol information for all clinical study types.

European Trial Register of EU studies.